Simulect
is contraindicated during pregnancy and lactation. Basiliximab has
potentially hazardous pharmacological effects with respect to the course
of gestation and the suckling neonate exposed to basiliximab in breast
milk. This concern is based on basiliximab's immunosuppressive action.
Women of childbearing potential must use adequate contraception to
prevent pregnancy and continue its use for an additional 8 weeks after
the last dose of Simulect.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
